AACR 2023 | Optimizing combination therapies to overcome PARP inhibitor resistance

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on overcoming PARP inhibitor resistance through rational combinations in the clinic. Genomic stability arising from DNA damage response (DDR) and/or increased replication stress is a key hallmark of cancer. Dr Yap provides an overview of the latest advances in biomarker-driven synthetic lethal combination treatment strategies for various cancers. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.